4
Changes in Ownership
AGIOS PHARMACEUTICALS, INC. Filed Acc 0001439222-24-000142
Director sold 20,000 shares at an average $55.86 ($1,117,147)
- Director acquired 20,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Ballal Rahul D. · Director
Table I: Non-derivative
7 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2024-11-07 | Exercise or conversion : show line 1 in the form 10b5-1 | +10,000 | $25.99 | $259,900 | 17,992 | D |
| 2024-11-07 | Sale : show line 2 in the form 10b5-1 | −8,132 | $53.32 | $433,598 | 9,860 | D |
| 2024-11-07 | Sale : show line 3 in the form 10b5-1 | −1,868 | $54.41 | $101,638 | 7,992 | D |
| 2024-11-08 | Exercise or conversion : show line 4 in the form 10b5-1 | +10,000 | $25.99 | $259,900 | 17,992 | D |
| 2024-11-08 | Sale : show line 5 in the form 10b5-1 | −3,571 | $57.24 | $204,404 | 14,421 | D |
| 2024-11-08 | Sale : show line 6 in the form 10b5-1 | −4,929 | $58.57 | $288,692 | 9,492 | D |
| 2024-11-08 | Sale : show line 7 in the form 10b5-1 | −1,500 | $59.21 | $88,815 | 7,992 | D |
| Open-market sales · 20,000 sh · avg $55.86 · $1,117,147 | ||||||
Table II: Derivative
2 lines| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2024-11-07 | Exercise or conversion : show line 8 in the form 10b5-1 Stock option (right to buy) | −10,000 | 27,947 | D |
| 2024-11-08 | Exercise or conversion : show line 9 in the form 10b5-1 Stock option (right to buy) | −10,000 | 17,947 | D |
Loading xslF345X05/wk-form4_1731445769.xml…